A Phase 3b Continuation study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in Previously Treated Patients with Severe Hemophilia A

Trial Profile

A Phase 3b Continuation study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in Previously Treated Patients with Severe Hemophilia A

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2018

At a glance

  • Drugs Rurioctocog alfa pegol (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 25 Apr 2018 This study has been completed in Poland (End date: 2018-02-05).
    • 05 Apr 2018 This trial was completed in Spain (end date: 2018-03-02)
    • 25 Mar 2018 This trial was completed in Lithuania (end date: 2018-03-02)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top